ArticleThe American journal of gastroenterology2025
Thiopurines and Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus and Inflammatory Bowel Disease Pregnancies.
Article in The American journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update on Pregnancy in Inflammatory Bowel Disease.Gastroenterology & hepatology · 2026Article
- The Latest on Intrahepatic Cholestasis of Pregnancy - Update 2026.Geburtshilfe und Frauenheilkunde · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe objective of this study was to examine the effects of thiopurine exposure during pregnancy on intrahepatic cholestasis of pregnancy (ICP) in systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD) pregnancies using nationwide data from Swedish healthcare registers.
methodsThis register-based cohort study included all singleton pregnancies with prevalent SLE or IBD in Sweden, 2007-2022. Exposure was ≥1 dispensation for azathioprine or 6-mercaptopurine from last menstrual period date to 1 day before delivery or before ICP diagnosis vs no dispensation. ICP diagnosis was identified with ICD-10 code O26.6 in inpatient or outpatient care. Propensity score matching (1 thiopurine-exposed and 2 thiopurine-unexposed) controlled for confounding factors (e.g., maternal smoking, body mass index, parity, IBD subtypes, glucocorticoids, and advanced therapies). Modified Poisson models were used to estimate risk ratios (RRs) and 95% confidence intervals (CIs).
resultsIn SLE, ICP occurred in 14 of 297 (4.7%) thiopurine-exposed pregnancies vs 11 of 594 (1.9%) matched unexposed pregnancies (adjusted RR 3.06, 95% CI 1.36-6.90; adjusted risk difference 4%, 95% CI 1%-6%). In IBD, ICP developed in 140 of 1,924 (7.3%) exposed pregnancies vs 36 of 3,848 (0.9%) matched unexposed pregnancies (adjusted RR 7.78, 95% CI 5.41-11.17; adjusted risk difference 6%, 95% CI 5%-8%). Sensitivity and subgroup analyses by ICP history, pregestational hypertension, renal diseases, liver diseases, glucocorticoid use, IBD subtypes, and thiopurine substance, and comparing thiopurines with tumor necrosis factor inhibitors exposure during pregnancy provided consistent results. DISCUSSION: In SLE and IBD, thiopurine exposure during pregnancy was associated with an increased risk of ICP, regardless of ICP history, hypertension, renal diseases, liver diseases, and glucocorticoid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.